This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Janux Therapeutics (JANX) Moves 6.5% Higher: Will This Strength Last?
by Zacks Equity Research
Janux Therapeutics (JANX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Janux Therapeutics (JANX) delivered earnings and revenue surprises of 65.63% and 1,078.41%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of -0.43% and 5.68%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's What Could Help Janux Therapeutics (JANX) Maintain Its Recent Price Strength
by Zacks Equity Research
Janux Therapeutics (JANX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors
by Zacks Equity Research
Janux (JANX) stock surges after some reports claim that the company is exploring opportunities for a potential sale following buyout offers from big pharma companies.
Janux Therapeutics (JANX) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Janux Therapeutics (JANX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Wall Street Analysts Think Janux Therapeutics (JANX) Could Surge 40.3%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 40.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
After Plunging -11.78% in 4 Weeks, Here's Why the Trend Might Reverse for Janux Therapeutics (JANX)
by Zacks Equity Research
Janux Therapeutics (JANX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Janux Therapeutics (JANX) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Janux Therapeutics (JANX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Believe Janux Therapeutics (JANX) Could Rally 57.47%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 57.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The Zacks Analyst Blog Highlights Janux Therapeutics, SoundHound, Root, Equillium and CleanSpark
by Zacks Equity Research
Janux Therapeutics, SoundHound, Root, Equillium and CleanSpark are included in this Analyst Blog.
5 Stocks That More Than Doubled in February
by Sweta Killa
Janux Therapeutics (JANX), SoundHound (SOUN), ROOT, Equillium (EQ) and CleanSpark (CLSK) more than doubled in February.
Recent Price Trend in Janux Therapeutics, Inc. (JANX) is Your Friend, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Janux Therapeutics, Inc. (JANX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Janux Therapeutics, Inc. (JANX) Moves 5.6% Higher: Will This Strength Last?
by Zacks Equity Research
Janux Therapeutics, Inc. (JANX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Inovio (INO) Moves 17.4% Higher: Will This Strength Last?
by Zacks Equity Research
Inovio (INO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Does Janux Therapeutics, Inc. (JANX) Have the Potential to Rally 205.5% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 205.5% in Janux Therapeutics, Inc. (JANX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts See a 220.17% Upside in Janux Therapeutics, Inc. (JANX): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 220.2% upside potential for Janux Therapeutics, Inc. (JANX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Janux Therapeutics, Inc. (JANX) Loses -34.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for Janux Therapeutics, Inc. (JANX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Wall Street Analysts Think Janux Therapeutics, Inc. (JANX) Could Surge 120.82%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 120.8% in Janux Therapeutics, Inc. (JANX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Janux Therapeutics, Inc. (JANX) delivered earnings and revenue surprises of 19.23% and 15.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About Janux Therapeutics, Inc. (JANX) Rating Upgrade to Buy
by Zacks Equity Research
Janux Therapeutics, Inc. (JANX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Believe Janux Therapeutics, Inc. (JANX) Could Rally 120.65%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 120.7% upside potential for Janux Therapeutics, Inc. (JANX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Janux Therapeutics, Inc. (JANX) delivered earnings and revenue surprises of 14.29% and 21.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Entera Bio Ltd. (ENTX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Entera Bio Ltd. (ENTX) delivered earnings and revenue surprises of 33.33% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Janux Therapeutics, Inc. (JANX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Janux Therapeutics, Inc. (JANX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.